STEALTH BIOTHERAPEUTICS CORP (MITO)       0.32  0 (-1.36%)

0.32  0 (-1.36%)

US85789A1051 - ADR


Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MITO. MITO was compared to 631 industry peers in the Biotechnology industry. Both the profitability and financial health of MITO have multiple concerns. MITO has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

0

The profitability ratios for MITO are negative, so there is not much use analyzing them.
MITO has a Return On Assets of -143.50%. This is below the industry average of -44.83%. 89% of the industry peers outperform MITO.

MITO has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for MITO.
VS Industry

ROA (-143.5%) VS Industry: 11% outperformed.

-950.38
52.28

Valuation

Valuation Rating

0

MITO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MITO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

1

MITO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.

Based on estimates for the next 5 years, MITO will show a small growth in Earnings Per Share. The EPS will grow by 4.98% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 0% 23.5% 16.73% 7.29% 4.98%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

2

MITO has a Current Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
MITO has a Quick Ratio of 3.68. This indicates that MITO is financially healthy and has no problem in meeting its short term obligations.
When comparing the Current Ratio of MITO to the average industry Current Ratio of 6.16, MITO is less able to pay its short term obligations than its industry peers.

Compared to an average industry Quick Ratio of 6.05, MITO is worse placed to pay its short term obligations than its industry peers.
MITO has a negative Debt to Equity ratio (-0.26), which implies it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
MITO has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for MITO.
VS Industry

Quick Ratio (3.68) VS Industry: 32% outperformed.

0.02
84.53

Current Ratio (3.68) VS Industry: 31% outperformed.

0.02
85.09

Dividend

Dividend Rating

0

MITO does not give a dividend.

MITO Daily chart

STEALTH BIOTHERAPEUTICS CORP0.32

NASDAQ:MITO (11/15/2022, 7:00:01 PM)0 (-1.36%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-18 2022-11-18/bmo Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 1.22%
Market Cap 23.54M Analysts 82.86
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B N/A
EV/EBITDA -0.07
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 0% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 0%
EPS Next Y 23.5% EPS Next 2Y 16.73%
EPS Next 3Y 7.29% EPS Next 5Y 4.98%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 3.68 Quick Ratio 3.68
Altman-Z N/A F-Score 2
Debt/Equity -0.26 WACC N/A
ROIC/WACC N/A
Profitability
ROA -143.5% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA